Radiosensitization by combining an aurora kinase inhibitor with radiotherapy in hepatocellular carcinoma through cell cycle interruption

International Journal of Cancer

Volumn 135, Issue 2, 2014, Pages 492-501

  Lin, Zhong Zhe ^a   Chou, Chia Hung ^a   Cheng, Ann Lii ^a   Liu, Wei Lin ^a   Chia Hsien Cheng, Jason ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

aurora kinase; hepatocellular carcinoma; inhibitor; radiotherapy

Indexed keywords

AURORA KINASE INHIBITOR; CELL DNA; HISTONE H3; UNCLASSIFIED DRUG; VE 465;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL CYCLE PHASE; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; DOSIMETRY; DRUG EFFECT; DRUG POTENCY; ENZYME ACTIVITY; ENZYME ASSAY; FLOW CYTOMETRY; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

AURORA KINASE; HEPATOCELLULAR CARCINOMA; INHIBITOR; RADIOTHERAPY;

ANIMALS; APOPTOSIS; AURORA KINASES; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, SCID; PIPERAZINES; PROTEIN KINASE INHIBITORS; RADIATION-SENSITIZING AGENTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84900024688     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28682     Document Type: Article

References (28)

1. Krishnan S, Dawson LA, Seong J, Akine Y, Beddar S, Briere TM, Crane CH, Mornex F, et al. Radiotherapy for hepatocellular carcinoma: an overview. Ann Surg Oncol 2008; 15: 1015-24.
2. Cheng JCH, Chuang VP, Cheng SH, et al. Local radiotherapy with or without transcatheter arterial chemoemboliziation for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2000; 47: 435-42.
3. Dawson LA, Normolle D, Balter JM, et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 2002; 53: 810-21.
4. Cheng JCH, Wu JK, Huang CM, et al. Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication. Int J Radiat Oncol Biol Phys 2002; 54: 156-62.
5. Cheng JCH, Chou CH, Kuo ML, et al. Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappa B signal transduction pathway. Oncogene 2006; 25: 7009-18.
6. Wilkens L, Flemming P, Gebel M, et al. Induction of aneuploidy by increasing chromosomal instability during dedifferentiation of hepatocellular carcinoma. Proc Natl Acad Sci USA 2004; 101: 1309-14.
7. Keen N, Taylor S,. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004; 4: 927-36.
8. Jeng YM, Peng SY, Lin CY, et al. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 2004; 10: 2065-71.
9. Lin ZZ, Jeng YM, Hu FC, et al. Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC. BMC Cancer 2010; 10: 461.
10. Cheng AL, Lin ZZ, Hsu HC, et al. The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma. J Hepatol 2009; 50: 518-27.
11. Gandara DR, Gautschi O, Heighway J, et al. Aurora kinases as anticancer drug targets. Clin Cancer Res 2008; 14: 1639-48.
12. Deutsch E, Tao Y, Zhang P, et al. Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells. Br J Cancer 2007; 97: 1664-72.
13. Liu Q, Guan Z, Wang XR, et al. Aurora-a, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells. Cancer Res 2007; 67: 10436-44.
14. Deutsch E, Tao Y, Zhang P, et al. Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152. Oncogene 2008; 27: 3244-55.
15. Lu B, Kim KW, Mutter RW, et al. Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests. Int J Radiat Oncol Biol Phys 2007; 67: 1519-25.
16. Chen CS, Kulp SK, Chen CS, et al. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Clin Cancer Res 2006; 12: 5199-206.
17. Cabibbo G, Latteri F, Antonucci M, et al. Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Clin Pract Gastr 2009; 6: 159-69.
18. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. New Engl J Med 2008; 359: 378-90.
19. Cheng AL, Kang YK, Chen ZD, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
20. Seong J, Park HC, Han KH, et al. Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: A retrospective study of 158 patients. Int J Radiat Oncol Biol Phys 2003; 55: 329-36.
21. Dawson LA, McGinn CJ, Normolle D, et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 2000; 18: 2210-18.
22. Timmerman RD, Kavanagh BD, Cho LC, Papiez L, Xing L,. Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol 2007; 25: 947-52.
23. Kroemer G, Zhang P, Castedo M, et al. Caspase independence of radio-induced cell death. Oncogene 2006; 25: 7758-70.
24. Kroemer G, Tao YG, Leteur C, et al. The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe. Cell Cycle 2009; 8: 3172-81.
25. Miller KM, Harrington EA, Bebbington D, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10: 262-67.
26. Keyomarsi K, Pawlik TM,. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 2004; 59: 928-42.
27. Taylor SS, Ditchfield C, Johnson VL, et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 2003; 161: 267-80.
28. Shapiro GI, Gizatullin F, Yao Y, et al. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res 2006; 66: 7668-77.